ICH Good Clinical Practice (GCP) for Certified Clinical Research Coordinator (CCRC) Practice Exam

These questions are part of the practice quiz. Start practicing

• What does the IRB/IEC conduct with regard to trials?
• Which concept ensures that trial results are not biased by the method of assigning participants to groups?
• Before starting the trial, how should regulatory submissions be dated?
• Informing the subject's primary physician about participation is recommended under what condition?
• Phase IV objectives may include which of the following?
• What is the written report from the monitor to the sponsor after each site visit or other trial-related communication called?
• Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by expectation, benefits associated with participation, or hierarchical retaliation are referred to as what?
• Which term is a declaration of confirmation by the auditor that an audit has taken place?
• The term used for the physical and mental well-being of the trial subjects is what?
• Which principle guides respect for participants and an appropriate risk-benefit assessment in trials?
• If a publication policy is not addressed in a separate agreement, what should be established regarding publication of trial results?
• What is the primary purpose of the Investigator's Brochure?
• Which statement is not described as part of the Investigator's Brochure's purpose?
• What is the purpose of Information Given to Trial Subject -- Informed Consent Form?
• What determinations should the sponsor make for the investigational product regarding storage?
• Which statement best describes subject exclusion criteria?
• Which statement best describes the packaging objective for investigational product(s)?
• The role of attending the informed consent process if the subject or legal representative cannot read is associated with which role?
• In describing the investigational product's physical, chemical, and pharmaceutical properties, which item must be included?
• Which design is used to facilitate interim analyses in clinical trials?
• When preparing the clinical study report, what should the summary of the clinical database include?
• Which statement best describes the primary variable in a clinical trial?
• Which document records the identity, purity, and strength of investigational products to be used in the trial?
• Which statement best describes the purpose of Any Other Written Information provided to trial subjects?
• What is the sponsor's responsibility regarding site access for monitoring, auditing, and inspection?
• Which bodies have the power to regulate clinical trials?
• In selecting a control group, which statement best describes acceptable comparisons?
• Which statement accurately describes language in the informed consent process regarding waiving legal rights?
• What elements should be included in the Phase IV study design?
• Which of the following describes the Per Protocol Set's components?
• In electronic trial data handling, which statement reflects a requirement to protect data integrity?
• Who is responsible for selecting investigators/institutions?
• Which statement best describes data quality requirements for CRFs and required reports?
• The sponsor should update the Investigator's Brochure in which scenario?
• What must investigators maintain to demonstrate that subjects were provided the doses specified by the protocol and to reconcile all investigational product(s) received from the sponsor?
• What should the analysis plan consider regarding early withdrawals and protocol violations?
• What role do designated medical personnel play in the trial?
• Upon completion of the trial, what should the investigator do?
• Which statement best describes the broad aim of the development plan for a new drug?
• Before starting a trial, which statement about IRB approval is correct?
• In emergency enrollment where prior consent is not possible, which statement is NOT correct?
• When a subject withdraws due to safety concerns, which data should be documented?
• Who is responsible for submitting the final report by the investigator to IRB/IEC and to regulatory authorities where required?
• Where should essential documents be located?
• Which term is defined as a standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected?
• Under what circumstance may the IRB/IEC require that more information be given to subjects beyond standard guidance?
• The extent and nature of monitoring should be based on considerations such as objective, purpose, design, complexity, blinding, size, and endpoints. True or False?
• Which criterion justifies early termination of a trial?
• IRB/IEC procedures should be...
• Clinical trials should be conducted in accordance with ethical principles originating from which source?
• Which term best describes documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced?
• Before informed consent may be obtained, what should the investigator provide?
• In a Human Pharmacology study, which objective is typically included?
• In a trial with more than one presentation or use, how should safety reporting be conducted?
• During Monitoring Procedures, after each site visit, what must a monitoring report include?
• How long should sponsor-specific essential documents be retained?
• Which design is defined as evaluating two or more treatments simultaneously through varying combinations and possible interactions?
• What does blinding accomplish in a trial?
• Which term is defined as a printed, optical, or electronic document designed to record all protocol-required information to be reported to the sponsor on each trial subject?
• Which statement correctly describes the relationship between Adverse Drug Reaction and Adverse Event?
• Which trial design randomizes participants to two or more arms, each arm receiving a different treatment?
• What document provides detailed, written instructions to achieve uniformity of performance of a specific function?
• Which element should include the power considerations when determining sample size?
• Which term denotes the protection of a sponsor's proprietary information and participant identities from unauthorized disclosure?
• If a single primary variable cannot be selected from multiple measurements, what strategy is recommended?
• Which term is a committee that a sponsor may organize to coordinate the conduct of a multicenter trial?
• Which term describes signs or diseases temporally associated with the use of a medicinal product?
• What is the required documentation for informed consent?
• Data transformation in analysis is used to do what?
• Which statement best describes the close-out documentation requirements?
• If a trial-related duty is not transferred to the CRO, who retains that duty?
• What is required regarding follow-up information for expedited ADR reports?
• What is the compilation of clinical and nonclinical data on the investigational products relevant to the study called?
• Which statement correctly describes the Full Analysis Set?
• The Therapeutic Use category is associated with which of the following?
• What document records revisions to normal values/ranges used for medical, laboratory, or technical procedures included in the protocol?
• Which statement correctly lists the minimum criteria for regulatory reporting of ADRs?
• Which statement best describes the efficacy assessment in a clinical trial?
• Which statement describes how monitors should handle standard operating procedures?
• Which document records revisions to trial documents that take effect during the trial?
• Which section addresses the reporting of reactions associated with active comparator or placebo treatment?
• Who must notify the sponsor of serious adverse events and related reports?
• Which statement best describes a monitor's responsibility regarding informed consent?
• Which topic focuses on the methods for statistical evaluation in a trial?
• Where are the analysis sets typically defined in a clinical trial protocol?
• Which member of the trial team is designated and supervised by the investigator at the trial site to perform critical trial-related procedures and/or to make important trial-related decisions?
• Which statement best reflects the requirement regarding coercion or undue influence in trial participation?
• Which element describes how long subjects participate and when follow-up occurs, including subsequent trial periods?
• What follow-up is advised for subjects who withdraw from treatment?
• During and after participation, what is the investigator's obligation regarding adverse events and significant laboratory values?
• How often should the IRB/IEC conduct continuing review of ongoing trials, considering risk level?
• Prior to supplying investigational product to a trial site, what must the sponsor obtain?
• The sponsor should utilize qualified individuals throughout all stages to do what?
• How should the sponsor inform investigators about the need for record attention?
• What is a primary purpose of Phase IV studies?
• The sponsor's procedures should include actions for unused investigational product. Which action is correct?
• What must be described and justified regarding the investigational product?
• When do Phase IV studies occur in the drug development lifecycle?
• Which item provides the description of the population to be studied in the context of Background Information?
• Which statement about the Subject Screening Log is true?
• Which role is an individual who both initiates and conducts a trial and under whose immediate direction the investigational product is administered to a subject?
• What term describes the planned and systematic actions to ensure trial activities comply with GCP and regulatory requirements?
• In a clinical trial, which entity takes responsibility for initiation, management, and financing of the trial?
• Which statement best describes the handling of changes or corrections to the CRF?
• Which statement best describes the investigator's obligation to communicate with the IRB/IEC?
• Which of the following should the IRB/IEC obtain to verify investigator qualifications?
• What must be obtained before initiating any protocol deviation?
• How should the investigational product(s) be stored?
• Which document updates the Investigator's Brochure during the trial?
• Prior to the trial, what must be obtained regarding the consent forms?
• If a trial is prematurely terminated or suspended, what information should be promptly communicated?
• Adverse events and/or laboratory abnormalities identified as critical to safety evaluations should be reported to the sponsor according to what?
• Where should the financial aspects of the trial be documented?
• In Phase I, which objective may be conducted as a secondary objective?
• What must be obtained from every subject prior to clinical trial participation?
• In GCP, how are efficacy data distinguished from safety data?
• Which records document that consent is obtained in accordance with GCP and protocol and dated prior to participation of each subject in trial, and also document direct access permission?
• The IRB/IEC should retain all relevant records for a period of at least how long after completion?
• To document that compensation to subjects for trial-related injury will be available, which locations are listed for documentation?
• Which element describes the methods and timing for assessing, recording, and analyzing efficacy parameters?
• Which items should be included in the investigational product accountability records?
• The sponsor's audit plan and procedures should be guided by which factors?
• What is the stated general expectation about on-site monitoring in trial monitoring guidance?
• Which statement best characterizes the design techniques to avoid bias in clinical trials?
• Which elements are included in the subject withdrawal criteria and procedure?
• Which statement best describes Quality Assurance in clinical trials?
• Which factor is essential when selecting auditors?
• What role do data monitoring committees (DMC/DSMB) play in relation to the clinical database?
• Which statement about Categorized Variables is correct?
• What does the term 'Expectedness' refer to in the context of an ADR?
• Which term describes the ongoing evaluation of trial progress and subject safety by a monitor, and the reporting of findings to the sponsor?
• Which term describes the process of assigning trial subjects to treatment or control groups using chance to reduce bias?
• An individual who participates in a clinical trial, either as a recipient of the investigational product or as a control, is called what?
• Before initiating a trial, which approvals must the investigator obtain from the IRB/IEC?
• During the trial, which entity monitors safety data continuously?
• What is the purpose of the subject identification code list?
• Interim analyses may lead to early stopping if which conditions are met?
• Interim analysis and early stopping are used to compare treatment arms with respect to what?
• What ensures that each individual involved in conducting a trial is qualified by education, training, and experience to perform their task?
• Which statement about the scope of trials is accurate?
• Which statement best reflects a monitor's qualification responsibilities?
• Which statement best describes sponsor obligation in investigator selection?
• The sponsor should submit to regulatory authorities all safety updates and periodic reports as required by which of the following?
• Who is primarily responsible for summarizing safety data in the clinical report?
• Which term refers to any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product, and/or to identify adverse reactions, and/or to study absorption, distribution, metabolism, and excretion of an investigational product with the object of ascertaining its safety and/or efficacy?
• In emergency situations where prior consent is not possible, which statement is correct?
• Early nonclinical safety studies should provide information to support which item related to first‑in‑human testing?
• What must be included about the reporting source in expedited ADR reports?
• The sponsor's system for the disposition of unused IP should ensure what?
• Who is responsible for retaining trial-related essential documents until the sponsor informs they are no longer needed?
• Where should the finalized CRFs be kept after completion and which copy is retained by the sponsor?
• The Introduction should provide the general approach to what?
• Who should sign off on changes or corrections to CRFs made by sponsor-designated representatives?
• Which document records the location and identification of retained body fluids/tissue samples if assays need to be repeated?
• Which document confirms that the site is suitable for the trial?
• What is the purpose of providing relevant and current scientific information about the investigational product to the investigator?
• Which document records treatment allocation and any decoding events and is maintained to support blinding integrity?
• Which document confirms the formal written agreement among the involved parties before the study begins?
• Which statement best reflects the Marketing Experience section?
• What describes the procedures for tracking the investigational products, including placebos and comparators?
• What factors influence the sample size in a clinical trial?
• What term refers to detailed, written instructions to achieve uniformity of the performance of a specific function?
• Which action documents that the investigator or authorized staff confirms the observations recorded in the Case Report Form (CRF)?
• What is the primary purpose of expedited SUSAR reporting to regulatory authorities?
• Which document lists all subjects enrolled and is kept confidential for potential follow-up?
• Who is the person primarily responsible for the proper conduct of the trial at the site?
• Which of the following best describes the Therapeutic Confirmatory objectives?
• The method and manner of compensation to trial subjects should...
• Interim or annual reports to regulatory authorities are typically provided by which party?
• Who is responsible for the accuracy of the clinical database summary?
• Source Documents: What is the purpose of source documents in a clinical trial?
• An adverse reaction, the nature or severity of which is not consistent with the applicable product information, is known as what?
• What should be signed to confirm agreement to the protocol?
• What is the primary aim of trial monitoring?
• Who is responsible for investigational product accountability at the trial site(s)?
• The Development Plan considerations address which of the following aspects?
• What must QA/QC ensure about data?
• Which document is used to document the financial agreement between the investigator/institution and the sponsor for the trial?
• Which actions should be reported promptly to the IRB/IEC?
• Which topic is addressed by the section that covers data integrity and computer software validity?
• What must be specified in the protocol regarding access to source data and documents?
• To preserve confidentiality, which identification method should be used in SAE reporting?
• In the Background Information section, which item provides details about the investigational product?
• Which statement is true about voluntary participation and withdrawal?
• In Phase I, what is the primary objective?
• Which design assigns a sequence of two or more treatments to the same participant, allowing them to serve as their own control?
• Which activities are included in the IRB/IEC's responsibilities related to meetings?
• Which two roles are typically responsible for safety data collection and reporting in a trial?
• Who should be responsible for all trial-related medical decisions?
• Before trial initiation, which body’s approval or favorable opinion is required for the protocol?
• Which action should the investigator take if a trial is prematurely terminated or suspended?
• Which statement correctly describes sponsor auditing procedures?
• Which statement best describes medications permitted before and/or during the trial?
• What is the primary purpose of protection of clinical trial subjects under GCP?
• Which topic involves evaluating the safety and tolerability of a therapy in a clinical trial?
• Who should vote on trial-related matters?
• Which document identifies the IRB/IEC approval (dated and documented) of trial related documents?
• Which statement describes the purpose of keeping essential documents post-trial?
• Trials to Show Equivalence or Non-inferiority are divided into two major objective-based categories. What are these two categories?
• A Therapeutic Confirmatory study primarily aims to do which?
• Phase II primary objective?
• All other serious, unexpected ADRs should be filed within how many calendar days after first knowledge?
• Which document contains pharmacology, toxicology, and prior human experience data on the investigational product to support human studies?
• What should be maintained by the IRB/IEC as part of its records?
• Which statement about access to source data should be included in the protocol or written agreement?
• Which item is NOT a required element of IRB/IEC confirmation of review?
• Which records changes, additions, or corrections made to the Case Report Form after initial data were recorded?
• Which statement best describes how missing, unused, and spurious data should be handled in a GCP trial?
• Which documentation category tracks certification, accreditation, QC, external QA, or other validation of procedures used in the protocol?
• Which statement describes monitoring guidance for procedures?
• Group sequential designs are used to facilitate the conduct of interim analyses.
• Under what circumstances might multiple primary variables be appropriate?
• To monitor adequately, monitors should be thoroughly familiar with which of the following?
• Which statement best reflects a general principle of ICH GCP regarding subject protection?
• What is required when transferring any trial-related duty to a CRO?
• Which statement is a required characteristic of changes or corrections to CRFs?
• What statement best describes the relationship between exploratory and confirmatory trials?
• What is the role of the investigator in IRB/IEC deliberations?
• The primary aim of protecting clinical trial subjects is to ensure what?
• What do you call a clinical trial conducted according to a single protocol but at more than one site?
• Which topic is addressed by procedures for monitoring subject compliance?
• Which description is required to justify the number of subjects enrolled?
• Which document records shipment dates, batch numbers, and the method of shipment for investigational products and trial-related materials, enabling tracking and accountability?
• Which statement correctly reflects confidentiality of records in publications?
• What is required before enrolling any subject in a trial?
• Which document documents chronological enrollment of subjects by trial number?
• Which term refers to adherence to trial-related requirements and Good Clinical Practice (GCP) requirements?
• A transfer of ownership of trial data should be reported to which entity?
• Which document would you reference to verify the IRB/IEC approval status and its date/version information?
• If changes significantly affect the conduct of the trial or increase risk to subjects, how should the investigator report?
• What document records site visits by, and findings of, the monitor?
• Who may request evidence of the investigator's qualifications?
• Which statement expresses the requirement that participant safety and well-being take precedence over scientific or societal interests?
• Post-study events refer to serious adverse events that occurred after completion of a clinical study. In such cases, who is typically responsible for reporting to the sponsor?
• When planning trials, what should the sponsor ensure regarding safety and efficacy data?
• Which term is used to describe a method where a participant or investigator is unaware of the treatment assignment?
• Which activity is a monitor's responsibility to ensure the trial is conducted and documented properly?
• During the clinical conduct of the trial, which category includes all documents required in the initial phase plus the following?
• Which adverse drug reactions (ADRs) require expedited reporting to all concerned investigators/institutions, IRBs/IEC(s) where required, and regulatory authorities?
• What should the Summary emphasize?
• Does the protocol specify whether and how replacement of withdrawn subjects may occur?
• The subtopic 'Evaluation and Reporting' addresses which aspect of trial data?
• 4.5.2 states about deviations without agreement
• Which term refers to original documents, data, and records?
• Which requirement ensures that a trial's conduct aligns with approved procedures?
• What must a monitoring report include after each site visit?
• What is the recommended approach when presenting conclusions about efficacy in the summary?
• Which item should be described to ensure proper handling, labeling, and traceability of the investigational product during the trial?
• Which term is a written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report?
• What is the purpose of adjusting significance and confidence levels?
• Which term describes a procedure in which one or more parties to the trial are kept unaware of the treatment assignment?
• On request from monitor, auditor, IRB/IEC, or regulatory authority, what should the investigator do?
• Which document serves as the formal record that a subject has given informed consent and is used as part of trial data?
• Which topics are encompassed by the Estimation, Confidence Intervals and Hypothesis Testing section?
• Which of the following is explicitly a Phase IV subcategory?
• What should the Introduction contain?
• May an IRB/IEC invite nonmembers with expertise for assistance?
• Which document confirms the IRB/IEC has reviewed and approved the protocol and includes the official date of approval?
• Which document is used to document that an audit was performed, if available?
• What information describes the expected duration of subject participation and the sequence of all trial periods?
• Which term means prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity?
• Which statement best describes the focus of the Development Plan Considerations?
• Which term is the formal written summary of the audit findings?
• Which statement best captures the requirement for investigator qualifications?
• What should the sponsor provide when regulatory requirements require coverage for trial-related injuries?
• Which term refers to an independent body responsible for protecting rights, safety, and well-being of human subjects by reviewing, approving, and providing continuing review of trial protocols and informed consent documents?
• Which component provides the procedures for eliciting reports of and for recording and reporting adverse events and intercurrent illnesses?
• The CRO should implement which of the following quality processes?
• What form should the Investigator's Brochure information take?
• During participation, what must be provided to the subject when updates to consent are made?
• Which aspect must be described about the investigational product to ensure proper administration and traceability?
• Which statement should be included in the statistical plan to describe interim analysis timing?
• What population is typically used for safety analyses in a GCP-compliant trial?
• If a deviation is implemented to eliminate an immediate hazard, what must be done?
• Which bodies may perform inspections of trial data and sites as part of QA activities?
• Which body must approve the inclusion of subjects for whom consent may be provided by a legally acceptable representative in non-therapeutic trials?
• What is the role of randomization in a clinical trial?
• Regulatory reporting of unexpected serious adverse drug reactions: to whom should these be reported?
• In blinded trials, what should the coding system include?
• Upon completion, what should be provided to the IRB/IEC?
• Who may vote or provide their opinion in IRB/IEC deliberations and discussions?
• Which topic describes the evaluation of safety and tolerability?
• Which option best describes what the introduction to nonclinical pharmacology should include?
• What action should be taken with safety updates and periodic reports?
• Which term refers to an independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial?
• Who bears responsibility for implementing and maintaining quality assurance and quality control systems in a trial?
• Under what condition is it recommended to inform the subject's primary physician about participation?
• The plan outlining what aspects of a trial are to be evaluated is described by which topic?
• Which scenario would be categorized as an 'Other Observations' item?
• Which item best demonstrates IRB/IEC compliance with GCP and applicable laws?
• According to GCP guidance, who should the sponsor utilize to supervise the overall conduct of the trial, handle statistics, verify data, conduct statistical analysis, and prepare trial reports?
• Essential Documents are those that demonstrate compliance with which standards?
• True or false: The initial expedited ADR report must identify the patient, the suspect product, the reporting source, and indicate that the event is serious and unexpected with a reasonable suspected causal relationship.
• Phase III is intended to provide an adequate basis for what?
• How should response variables be defined in the protocol?
• Which statement best describes the sponsor's responsibilities for the investigational product?
• What distinguishes an Adverse Drug Reaction (ADR) from a general Adverse Event (AE)?
• Which term refers to an individual or body authorized to consent on behalf of a prospective subject?
• Which of the following best reflects Phase IV objectives related to patient populations?
• Who may inspect trial records as part of QA and regulatory oversight?
• Which statement best describes the Per Protocol Set?
• What must be maintained for the randomization process and potential code-breaking?
• Which statement best describes a requirement of informed consent?
• What should be done with trial-related essential documents after the trial when there are still potential marketing applications?
• Which statement is true about trial-related injury is required in the consent?
• Which documents should the IRB/IEC obtain from the investigator?
• What actions should the investigator take to ensure correct use of the investigational product(s) by each subject?
• What is the purpose of the Subject Identification Code List?
• If a sponsor transfers trial-related duties to a CRO, who retains ultimate responsibility for the quality and integrity of the trial data?
• Under which circumstances may protocol deviations or changes be initiated without prior IRB/IEC approval?
• What term describes the act by a regulatory authority of conducting an official review of documents, facilities, records, and related resources for the trial?
• How should the language of the consent information be written?
• How should clinical study reports be documented?
• Which topic outlines how variables are chosen and how data are collected?
• Which term is an investigational or marketed product, or placebo, used as a reference in a clinical trial?
• Regarding randomization and unblinding, which statement is correct?
• Which statement best describes the design of a trial in terms of scientific quality?
• Which statement about exploratory trials is true?
• Which statement combines the enrollment number and power calculations to justify the trial size?
• The ethical principles underlying GCP and informed consent trace their origin to which document?
• Which term refers to the laws and regulations addressing the conduct of clinical trials of investigational products?
• Which statement is included to confirm compliance with protocol and regulatory requirements?
• True or False: Phase IV studies begin after drug approval.
• Before starting a trial, which element is most appropriate to be clearly specified in the protocol?
• Which data are considered source data in a GCP trial and should be recorded directly on the Case Report Form (CRF)?
• Which item must be included in the informed consent discussion and form? 4.8.9 content about risks and benefits etc.
• Which statement best describes IRB/IEC record retention duration?
• Why must the protocol specify the principal features of the proposed statistical analysis before starting?
• Sample size adjustment is used to account for what during a trial?
• Who should retain records of the changes and corrections to CRFs?
• In a multicenter trial, who is primarily responsible for ensuring standardized data collection across sites?
• What is a monitor's duty regarding CRF entries and source documents?
• Which topic covers handling data gaps and unusual values in data?
• Which document specifies the master randomization list?
• Which records document the qualifications of investigators and sub-investigators?
• Which document covers the decoding procedures for blinded trials?
• Which information must be provided for the qualified physician or dentist responsible for all trial-site medical decisions if the physician is not the investigator?
• Which topic is specifically addressed under pharmacokinetic studies?
• When a trial is terminated or suspended, which parties should be informed promptly and given reasons?
• Under Investigator-Adequate Resources, what is emphasized?
• Which entity should retain sponsor-specific essential documents related to the trial?
• Which term describes an individual responsible for the conduct of the clinical trial at a site?
• Which document demonstrates competence of the facility to perform required tests and support reliability of results?
• Which statement best describes the CRO's QA/QC duties?
• What must be included in informing the subject about the trial?
• What information should be provided for the clinical laboratories and other medical or technical departments involved in the trial?
• Phase I is most typically which kind of study?
• Which parties are responsible for maintaining documentation of regulatory authorities' authorization/approvals/notifications for protocol amendments and other documents?
• Why is blinded therapy case management included in expedited reporting guidelines?
• Which scenario best illustrates the scope of stopping rules within a trial protocol?
• Which statement best describes the purpose of maintaining randomization codes and code-breaking procedures?
• Who is the person responsible for the conduct of the clinical trial at a trial site?
• Investigators must permit which activities?
• Which document includes original records related to the trial, to medical treatment, and history of the subject and substantiates the trial data?
• Which items should the sponsor obtain to confirm IRB/IEC review and operation?
• The protocol should include a description of the trial's type or design and what else?
• The brochure's purpose supports investigators in assessing risk-benefit for which aspect?
• Accrual rate refers to which aspect of a trial?
• Which principle places the rights, safety, and well-being of the trial subjects as the most important considerations, taking precedence over science and society?
• Which statement about Multiple Primary Variables is true?
• What term describes a clinical trial conducted according to a single protocol but at more than one site?
• If the investigator terminates or suspends a trial without prior agreement of the sponsor, what is required?
• The investigator should comply with the protocol; what is required?
• Which element should be included regarding patients who stop treatment prematurely in Phase IV trials?
• When a death is reported in a clinical trial, what should the investigator provide to the sponsor and the IRB/IEC?
• Surrogate variables are used as reliable predictors of clinical benefit in various indications. Which option matches this idea?
• What documentation records agreements or significant discussions regarding trial administration, protocol violations, trial conduct, adverse event (AD) reporting?
• Medical expertise is applied in which area according to the guideline?
• For a non-therapeutic trial conducted with consent of the subject's legally acceptable representative, what must the IRB/IEC determine?
• Who is responsible for the medical care and medical decisions for trial subjects?
• What is the primary purpose of documenting normal values/ranges for medical, laboratory, or technical procedures included in the protocol?
• Which statement correctly describes expedited review for minor changes?
• When should the written informed consent form and any other written information be revised, and what approval is required before use?
• Which item is an example of 'Other Observations' in expedited reporting?
• The sponsor should utilize qualified individuals throughout all stages of the trial for which purpose?
• What should be done with the observations and findings of auditors?
• When must pharmacokinetic (PK) impact studies be available?
• Which statement best describes the purpose of subject inclusion criteria in a clinical trial?
• During the trial, to whom should the investigator provide documents subject to review?
• After reporting a fatal or life-threatening ADR within 7 days, by when should a more complete report typically be provided?
• Documentation of regulatory authorities' authorization/approvals/notifications required for protocol amendments and other documents should be kept by which parties?
• What does Direct Access refer to in the context of clinical trials?
• If the Investigator's Brochure is updated during the trial, what should be done?
• Which term describes a sponsor-organized group that coordinates the conduct of a multicenter trial?
• Which statement best describes what is involved in establishing the IRB/IEC's formal basis?
• Which statement best describes sponsor responsibilities related to direct access to source data for monitoring and regulatory inspections?
• As part of the investigator's written application to the IRB/IEC, what must be provided?
• Which of the following best describes what the IRB/IEC review should encompass?
• Which term refers to the operational techniques and activities undertaken within the quality assurance system to verify that requirements for quality of trial-related activities have been fulfilled?
• Which item defines the safety endpoints to be monitored and how they are measured?
• Which document records the method for randomization of the trial population?
• What term describes biomedical studies not performed on human subjects?
• Which statement best describes the documentation of trial finances?
• Informed Consent is defined as
• Why have multiple analysis sets?
• Noncompliance with protocol, SOPs, GCP, or regulatory requirements by an investigator or sponsor staff should lead to what action?
• Which statement best describes the tone of the Investigator's Brochure?
• Financing and insurance provisions should be described where if not addressed in a separate agreement?
• What should the investigator ensure about staffing and facilities for the trial?
• Which document confirms that investigational products have been used according to the protocol?
• When may regulatory authorities access audit reports if not routinely requested?
• Which item summarizes findings from nonclinical studies and clinical trials relevant to the trial?
• Which statement about auditors is correct?
• If the sponsor discontinues clinical development of an investigational product, how long should sponsor-specific essential documents be retained?
• Which document records that trial procedures were reviewed with the investigator and the investigator's trial staff?
• Data capture and processing in a trial can transfer data from the investigator to the sponsor through which media?
• What should be included in written information for payment?
• If prior consent of the trial subject or the subject's legally acceptable representative is not possible, what must the IRB/IEC determine?
• What should the Title Page potentially include according to the guidelines?
• The investigator should be thoroughly familiar with the appropriate use of the investigational products as described in which sources?
• Which statement about non-therapeutic trials with LAR consent is NOT correct?
• Outside consultant(s) may be appointed for what purpose?
• What is the purpose of reviewing the amount and method of payment to subjects?
• In multicenter trials, what should be provided when investigators collect additional data beyond the core protocol?
• If IRB/IEC requires changes to the protocol or consent, what should the sponsor obtain?
• What is the retention requirement for essential trial documents after a study ends in an ICH region?
• What information should be provided for the physician or dentist responsible for site medical decisions when this person is not the investigator?
• What documentation identifies the IRB/IEC review and approval and notes the version number and date of documents?
• Which role is designated and supervised by the investigator at the trial site to perform critical trial-related procedures?
• Which term describes documents that permit evaluation of the conduct of a study and the quality of the data produced?
• Which document demonstrates compliance with labeling regulations and the appropriateness of instructions provided to subjects?
• What is required to protect the confidentiality of records that could identify subjects?
• Which statement reflects a data security requirement for electronic data handling?
• The set of data elements (patient initials, suspected medicinal product, other treatments, details of the suspected ADR, details on the reporter, and administrative details) are used for expedited reports to ensure what?
• Which item is not included in the Introduction content?
• In trial documentation, which element identifies the laboratories and other departments involved?
• What is the role of an independent data-monitoring committee (IDMC) in a clinical trial?
• What edition-related information is suggested to be provided?
• What are the purposes of trial monitoring?
• Which topic covers subgroups, interactions, and covariates?
• Which statement describes investigator obligations under 5.6.2 a-d?
• For a fatal or life-threatening ADR, the initial notification must include which of the following elements?
• Prior to initiating a trial, what should be defined, established, and allocated?
• Which design approaches testing two or more treatments by using different combinations and evaluating potential interactions?
• Publication policy in GCP should be addressed where if not in a separate agreement?
• Which two techniques are described as measures to minimize bias in the trial?
• The location(s) where trial-related activities are actually conducted are referred to as what?
• Which term refers to a study conducted across more than one site to improve generalizability?
• Which description best captures the essential focus when selecting a dose range in development planning?
• In the Phase IV framework, which category specifically covers Studies of Drug Metabolites?
• Which item specifies the timing of any planned interim analysis?
• In a crossover design, what is a key benefit for treatment comparisons?
• Which description best characterizes study endpoints?
• Which document is listed as being located at both the investigator/institution and sponsor locations to reflect agreement on protocol/amendments and CRF?
• Which element details the type and duration of the follow-up of subjects after adverse events?
• After an SAE is reported immediately, what should follow?
• What is the primary purpose of a parallel group design?
• Phase IV studies may involve which of the following activities?
• When should IRB/IEC decisions be made?
• Which aspect most directly ensures the scientific integrity and credibility of a clinical trial's data?
• Which statement best describes sponsor's audit purpose?
• Which items must the IRB/IEC promptly notify the investigator in writing?
• Which action relates to the investigational product and is a monitor's responsibility?
• If data are transformed during processing, what must be possible?
• How is subject safety addressed in a GCP trial?
• Which document is used to document the agreement between the investigator and sponsor to the protocol/amendments and the CRF?
• Interim or annual reports are provided to which parties?
• Why must the protocol describe dosing schedules and follow-up periods for each treatment group?
• When any trial-related duties are transferred to a CRO, what must be specified in writing?
• Which statement best describes the 'Considerations for Individual Clinical Trials' category?
• Which item is NOT typically considered a key data element for expedited reports of serious adverse reactions?
• Which statement best describes how all clinical trial information should be treated?
• What is the key purpose of summarizing the clinical database in the report?
• Dose-response relationships can be evaluated in which phases of development?
• In SAE reporting, how should subjects be identified?
• Non-therapeutic trials conducted with consent of a legally acceptable representative should be conducted under which condition?
• Phase IV objectives may include the assessment of which type of parameters?
• Should records identifying the subject be kept confidential and identity remain confidential when results are published?
• Why should the Investigator's Brochure be updated?
• Which statement best describes data capture and processing responsibilities in GCP?
• Under what guideline condition may abbreviated study reports be acceptable?
• What term describes a unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name?
• Which description best matches an Impartial Witness in clinical trials?
• Which term describes the set of activities designed to ensure the trial's quality by monitoring compliance and processes, not by data itself?
• What does the IRB/IEC determine as appropriate for continuing review?
• Interim analyses may lead to early stopping when which conditions are met?
• How should study reports be prepared in relation to guidelines?
• If a subject cannot read, what is required during the consent discussion?
• What should be described when defining response variables?
• What term describes all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• What primarily determines the sample size of a clinical trial?
• What type of subject identification code should the sponsor use?
• What documentation verifies the qualifications and eligibility of new investigators and/or sub-investigators to conduct the trial?
• If the sponsor terminates or suspends a trial, what is the investigator's obligation?
• Which design typically involves conducting trials across multiple research sites?
• The physical and mental integrity of the subjects participating in a clinical trial is described as what?
• What must be provided to show the investigator's qualifications?
• Global Assessment Variables measure what in a clinical trial?
• Quality assurance activities require written SOPs. Who is responsible for implementing and maintaining QA/QC systems with written SOPs?
• Who is primarily responsible for supplying the investigational product to investigator sites?
• Who should retain sponsor-specific essential documents pertaining to the trial?
• Which term refers to the judgement and/or advice provided by an Independent Ethics Committee (IEC)?
• What is required when data on the CRF is derived from source documents?
• Who is permitted to vote on trial-related matters within an IRB/IEC?
• Which element defines how safety data are collected and reported?
• Which data are typically included under safety data in a clinical trial report?
• What should the protocol specify to minimize bias?
• What is the primary purpose of the coding in blinded trials?
• Adverse events reporting timeframe?
• Before the clinical phase of the trial commences, what should be documented?
• 4.5.4 describes what about deviations to eliminate immediate hazards?
• In a trial protocol, which elements must be explicitly defined as the primary and secondary outcomes to be measured?
• In GCP trials, what level of significance is commonly used for hypothesis testing?
• The monitor's responsibilities include ensuring that the trial is conducted and documented properly by carrying out activities when relevant. This is described in which section?
• Why might significance levels be adjusted when multiple analyses are performed?
• What should accompany the communication of new information to the subject to continue participation?
• Which activity describes the IRB/IEC's scheduling and notification responsibilities?
• What is the requirement regarding those who assist with the trial?
• What topics should be included in the Effects in Humans: Introduction with respect to pharmacokinetics data?
• Which term is a person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions?
• Which statement best describes why trial records are maintained?
• What information must be described about investigational products?
• Which documentation should the IRB/IEC consider to assess the investigator's qualifications for a proposed trial?
• Which information is included when discussing storage and handling?
• Which statement best defines an Adverse Event (AE) in a clinical trial?
• Expedited safety reports should comply with regulatory requirements and which ICH guideline?
• What best describes the investigator's obligation to IRB/IEC communication?
• Blinding aims to limit conscious and unconscious bias in which areas?
• What approach should be implemented to assure the quality of every aspect of the trial?
• What is the purpose of assigning unique code numbers to the investigational product(s) and to trial subjects?
• What should be documented regarding the responsibilities of coordinating and participating investigators before starting the trial?
• What is documented by Advertisement for Subject Recruitment?
• What is the term for a report of intermediate results and their evaluation based on analyses performed during the course of a trial?
• Which item should the sponsor obtain from the IRB/IEC to confirm GCP compliance?
• Which topic addresses the integrity of data and the validity of computer software used in data handling?
• Which term best describes the process of performing a formal review to ensure compliance with the protocol and SOPs?
• What is true about GMP in relation to investigational product coding and labeling?
• What should the Investigational Brochure describe regarding risks and monitoring?
• What is the primary purpose of QA/QC systems in GCP?
• Phase III primary objective?
• What is the purpose of the sponsor notifying investigators of safety information?
• Which term describes an investigator assigned the responsibility for the coordination of investigators at different centers participating in a multicenter trial?
• Considerations for the Development Plan emphasize which aspect?
• Which item is NOT a data element for expedited reports?
• In a dose-ranging program, what is the primary objective?
• Which document is used to document signatures and initials of all persons authorized to make entries and/or corrections on case report forms?
• In superiority trials, which approach most convincingly demonstrates efficacy?
• Which option best describes the criterion that ensures staff are qualified for their tasks?
• Which statement best describes an audit in clinical trials?
• Which documents guide the trial design, protocol, and conduct?
• What is the primary purpose of a sponsor's audit?
• If the IRB/IEC terminates or suspends its approval, what should the investigator do?
• In Phase I, which objective is described as Estimation of initial safety and tolerability?
• When should the investigator inform the subject about the need for medical care for intercurrent illness(es)?
• Which item ensures that references to literature and data relevant to the trial are included?
• Which records are required to document the shipment, receipt, disposition, return, and destruction of the investigational product?
• Which document contains the objective, design, methodology, and statistical considerations of a trial?
• Which entities should the sponsor promptly notify about findings that could affect subject safety, trial conduct, or the continued favorable opinion of the IRB/IEC?
• Who submits the final report by the investigator to IRB/IEC and, where applicable, to regulatory authorities?
• What must be documented regarding data changes to electronic systems?
• Deviations from or changes to the protocol should not be initiated without prior written IRB/IEC approval except in which circumstances?
• Which entities should sponsor-specific essential documents be retained for in conformance with regulatory requirements?
• All investigators must conduct the trial in strict compliance with which directive?
• Which factors determine the extent and nature of monitoring?
• What term describes the pharmaceutical form of an active ingredient or placebo that is tested or used as a reference in a clinical trial?
• What is the purpose of pre-specifying the statistical analysis in a protocol?
• What term refers to the act of overseeing the progress of a clinical trial and ensuring it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and regulatory requirements?
• What is the requirement for informing all persons assisting with the trial about the protocol and duties?
• Which topic specifically covers issues arising when therapy is blinded during a trial?
• What should be done regarding patient compliance in a trial?
• Equivalence and non-inferiority trials are divided into two major objective-based categories according to their goals. Which pair describes these categories?
• Which topic discusses an integrated summary of trial results?
• Which scenario qualifies as a Serious Adverse Event (SAE)?
• Which term describes permission to examine records and reports that are important to evaluation of a clinical trial?
• What should be described about the population to be studied?
• Which statement best describes how information in the Investigator's Brochure should be presented?
• Which document demonstrates that regulatory authorities have authorized/approved/notified the protocol prior to initiation of regulatory requirements?
• Investigational products should be manufactured, handled, and stored in accordance with which standard?
• Which party is responsible for the ongoing safety evaluation of the investigational product?
• Which is NOT a standard toxicology heading under nonclinical studies?
• Where should signature sheets be maintained?
• Who must sign and date the written informed consent prior to participation?
• In the Phase IV design, what aspect relates directly to safety monitoring?
• In trial planning, which element must be clearly specified in a protocol before the trial begins?
• What should be addressed in the nonclinical pharmacokinetics section?
• Which concept is primarily supported by documentation that ensures the integrity and accuracy of trial data?
• What does the term Investigator-Adequate Resources imply?
• If the trial is blinded, what must the investigator do in the event of any premature unblinding?
• What statement best describes the purpose of direct access to source data and documents in GCP inspections?
• What form must agreements between the sponsor and investigator or institution take?
• Regarding structural similarities to other known compounds, which statement is appropriate?
• Data transformation is typically used to?
• IRB/IEC should obtain information about payments to and compensation available to subjects.
• When may the investigator implement a deviation without prior IRB/IEC approval?
• Which statement best reflects the expected time frame for conducting and completing the trial?
• In multi-center trials, who is responsible for organization and selection of coordinating investigator(s)?
• Who should provide Curriculum Vitae and other documents evidencing qualifications of investigators and sub-investigators?
• Which ICH guideline covers the structure and content of clinical study reports?
• Which term is defined as any untoward medical occurrence in a patient or trial subject administered a pharmaceutical product, regardless of causal relation?
• The investigator should be aware of and comply with which requirements?
• Which term represents all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• Randomization provides a sound statistical basis for the evaluation of treatment effects. Which option best expresses this?
• Which statement accurately describes the use of documentation for all subjects who began trial procedures?
• Who should permit monitoring and auditing by the sponsor, and inspections by regulatory authorities?
• Which action ensures data can be recovered in case of system failure?
• Data handling and record keeping in a GCP trial should ensure which principle?
• Which term describes documentation that allows reconstruction of the course of events?
• Early nonclinical safety studies should provide information to support which of the following, EXCEPT?
• What should the Summary highlight according to the guidelines?
• Which statement best describes how an IRB/IEC should operate?
• The sponsor should maintain records for which activities related to the investigational product's lifecycle?
• Which document records the destruction of unused investigational products?
• Where are analysis sets defined in a protocol?
• What type of trial is designed to show that the investigational product is equivalent to, or not worse than, a reference treatment?
• Surrogate variables are used in indications where they are believed to be reliable predictors of clinical benefit. True or false?
• What must be provided to the IRB/IEC to obtain its favorable opinion?
• Which statement best describes IRB/IEC responsibilities?
• Labeling of investigational product(s) must comply with what?
• What does statistically controlled sampling in monitoring pertain to?
• One of the objectives of the ICH E8 document is to present an overview of the ICH clinical safety and efficacy documents and facilitate access to guidance pertinent to clinical trials. Which option best captures this objective?
• The design of case report forms (CRFs) in multicenter trials should capture what?
• Post-study adverse events are typically reported by the investigator to the sponsor. true or false?
• Exploratory trials should have clear and precise objectives.
• Which statement best describes pre-trial regulatory notification?
• Which body may be established by the sponsor to assess progress, safety data, and critical efficacy variables and to recommend continuation, modification, or termination?
• Which element describes the trial's design and includes a schematic diagram of its design, procedures, and stages?
• The investigator should ensure that the investigational product(s) are used only in accordance with what?
• Which statement best describes subject protection focus in ICH GCP general principles?
• Notification by sponsor and/or investigator to regulatory authorities and IRB/IECs of unexpected serious adverse drug reactions and other safety information is intended for which recipients?
• Which term identifies the formal approval by the IRB to conduct the trial at the site?
• What presentation is useful for safety and efficacy data across multiple trials by indications or subgroups?
• Which document shows the IRB/IEC is constituted in accordance with GCP?
• Which of the following describes recommended characteristics of an IRB/IEC?
• Which groups are explicitly included under Special Populations in Phase IV guidelines?
• Which term refers to the original documents, data, and records used during a clinical trial?
• Which statement best describes the focus of the Therapeutic Use category?
• After completion or termination, which set of documents should be retained?
• When new safety information becomes available during a trial, who must be informed of this information?
• Which document records that amendments and/or revisions have been subject to IRB/IEC review and were given approval/favorable opinion, and identifies the version number and date of the documents?
• Nonclinical studies focus on which areas to support initial human dose?
• Which design element helps ensure prognostic factors are balanced across treatment groups?
• Which statement about sponsor responsibility is true?
• If the IRB/IEC withdraws or suspends approval, what should be done?
• What is the primary rationale for using multiple analysis sets?
• Which term refers to the official review of documents, facilities, and records by a regulatory authority?
• What must the sponsor verify regarding a subject's consent for direct access to original medical records?
• What is the purpose of documenting retained body fluids/tissue samples?
• What must be included in the justification for sample size?
• In Phase II, what is the primary consideration for dosing and regimen?
• Which data are typically included under efficacy data in a clinical trial report?
• Which statement about source data verification is correct?
• If significant formulation changes are made during clinical development, what must be available prior to using the new formulation in clinical trials?
• What documentation certifies the identity, purity, and strength of investigational products to be used in the trial?
• What should the summary of efficacy data include to support conclusions about a treatment's effect?
• Which term is the affirmative decision of the IRB that the trial may be conducted at the site within constraints?
• What is the role of an Independent Data-Monitoring Committee (IDMC)?
• Which topic covers the set of subjects to be evaluated and the presentation of data?
• In the Effects in Humans: Introduction, which topics may be included when available?
• Which statement about payments to trial subjects is correct?
• Ethical considerations in a clinical trial include which of the following?
• The Full Analysis Set is designed to approximate which principle?
• Which topic is dedicated to the act of reporting study results?
• Fatal or life-threatening unexpected ADRs must be reported to regulatory authorities within what timeframe after first knowledge?
• Which document records the final accounting of investigational products at the site?
• Should changes in inclusion and exclusion criteria remain constant during recruitment?
• Who should be informed of storage determinations?
• Which term refers to the written evaluation provided by the sponsor's auditor summarizing the audit results?
• Which term describes all noxious and unintended responses to a medicinal product related to any dose?
• When a CRO has assumed trial-related duties, to whom do references to the sponsor apply?
• Which term refers to any medical or dental facility where clinical trials are conducted?
• Which aspects should the protocol’s analysis plan cover?
• To document the existence of the subject and substantiate integrity of trial data collected; to include original documents related to the trial, to medical treatment, and history of subject
• Which document confirms that all activities required for trial close-out are completed and copies of essential documents are filed?
• Which document addresses the financial aspects of the trial?
• Which item describes the known and potential risks and benefits to human subjects?
• What expenses information must be included in the consent?
• The Marketing Experience section should identify which information?
• The responsibility for medical care and medical decisions for trial subjects rests with which professional?
• Which statement about formulation details is correct?
• If new information becomes available that may affect a subject's willingness to continue participation, who should be informed?
• During the trial, what should the investigator provide to the IRB/IEC?
• What is required when protocol deviations occur?
• What payment information must be included in the consent?
• Which document describes the written description of a change to the protocol?
• Which statement about the Independent Data Monitoring Committee (IDMC) is true?
• Which statement best distinguishes Quality Control from Quality Assurance in GCP?
• The sponsor and the investigator/institution should sign the protocol, or an alternative document, to confirm agreement. What action confirms agreement?
• What is GMP's main aim for IP manufacturing?
• Freely given informed consent must be obtained from every subject prior to clinical trial participation. Which option reflects a key aspect of this requirement?
• Annual progress report to whom?
• Regardless of completion, what must be done with clinical trial reports?
• Which is a written description of a change to or formal clarification of a protocol?
• The plan for which variables are collected and how data are gathered is described by which topic?
• According to the material, the Investigator's Brochure serves to document which of the following?
• Which best describes how safety findings should be presented in the final report?
• Who informs the investigator when essential trial documents no longer need to be retained?
• Which trial type is an adequately controlled study in which hypotheses are stated in advance and evaluated to provide firm evidence of efficacy or safety?
• Which action is explicitly described as a sponsor responsibility related to stability and retention of the investigational product?
• What is the primary purpose of expedited safety reports in the ICH framework?
• Which statement describes a composite variable?
• When selecting subjects for a Phase IV study, which factors should be considered?
• What is required to ensure timely delivery of the investigational product to investigators?
• Which term is a description of a study described as a trial conducted in humans that is produced by integrating clinical and statistical descriptions in a single report?
• If a health issue is unrelated to the trial drug, how is it usually categorized?
• How often should investigators check that each subject is following the instructions for using the investigational product?
• Which document identifies subjects who entered pre-trial screening?
• What should the investigator do for any deviation from approved protocol?
• Before initiating the clinical trial(s), what should the sponsor submit to the appropriate authority(ies)?
• What type of review does the IRB/IEC perform for trials?
• Progress Report: How often should the investigator submit written summaries of trial status to the IRB/IEC?
• Which document describes how, in an emergency, the identity of blinded investigational product can be revealed without unblinding remaining subjects?
• Which statement is true about familiarization with the investigational product use?
• 4.5.1 summarizes which concept?
• What is required regarding the immediate SAE report?
• The nonclinical pharmacology section should include which of the following?
• Under what circumstances are interim results appropriate to include in the clinical study report?
• What action ensures compliance with GCP regarding oversight?
• In the context of Investigational Medicinal Products, which aspect should be well characterized in formulations used in clinical trials?
• Phase III typically includes further exploring which aspect in a broader population?
• Who is responsible for initiating, managing, and financing a clinical trial?
• Under monitoring guidance, which statement correctly describes the 5.18.1 purpose?
• Under what conditions may expedited review be provided for minor changes in ongoing trials?
• If a subject withdraws prematurely, what should the investigator do regarding the reasons?
• Which type of trial is designed to provide firm evidence of efficacy or safety?
• Development Methodology in the context of the development plan covers what?
• In a non-therapeutic trial, who normally must give consent and sign the written informed consent, unless an exception is justified?
• Which statement describes ensuring information for trial personnel about protocol and investigational products?
• When a subject withdraws from the trial, which data should be collected?
• Where is the timing of any planned interim analysis described?
• What documentation describes shipment dates, batch numbers, and method of shipment for investigational products to enable tracking and accountability?
• Which term is used for an ADR that is not described in the product labeling or Investigator's Brochure?
• Which statement ensures site-level enrollment targets are documented for multisite trials?
• Which statement accurately describes the staffing and facilities requirement?
• Which Phase I consideration relates to clearance and potential drug-drug interactions?
• Which statement best describes the sponsor's duty regarding costs of treatment for trial-related injuries?
• Which option best describes the Introduction's comprehensive content regarding the product?
• Which statement supports sample size justification?
• What does SUSAR stand for?
• Which statement best represents a core purpose of the ICH E8 document?
• In trials where enrollment can occur only with the consent of the subject's legally acceptable representative, if the subject is capable, what should occur regarding consent?
• If monitoring or auditing identifies serious and persistent noncompliance, what should the sponsor do?
• What should be done about deviations from the protocol?
• To document that there are written agreements among involved parties, which location is used?
• Written procedures for handling the investigational product should include which of the following?
• During trial reviews, special attention should be paid to trials that may include...
• Which document is used to determine the expectedness of an ADR?
• Which event would not typically be classified as a Serious Adverse Event?
• The document that presents the results and interpretations of a clinical trial is called what?
• Which section should include the description of the population to be studied?
• Which type of trial is primarily intended to provide firm evidence of efficacy or safety?
• Which entity is authorized under applicable law to consent on behalf of a prospective subject to participate in the trial?
• What is required before initiating a trial regarding Investigator's Brochure?
• Which statement is true about confidentiality and ongoing information for trial subjects?
• What must be included in the written information provided to subjects regarding payment?
• Which term best describes the formal opinion issued by an Independent Ethics Committee regarding trial ethics and participant safety?
• Which are the objectives associated with Therapeutic Exploratory studies?
• What should be adequate to support the proposed clinical trial regarding the investigational product?
• In multisite trials, what should be specified regarding enrollment?
• Which design evaluates two or more treatments simultaneously by varying combinations of treatments?
• Which topic encompasses trial monitoring and interim analyses?
• Which combination best describes the data transfer media used in data capture and processing?
• What is the requirement for retention and archiving of trial records?
• The plan for the scope of evaluation in a clinical trial is described by which topic?
• What is the recommended timing for reporting SAEs to the sponsor per GCP?
• Which option lists the acceptable locations for documenting shipping records for investigational products?
• What should the investigator maintain regarding significant trial-related duties?
• During participation, what must be provided to the subject regarding consent updates?
• When the sponsor discontinues clinical development of an investigational product, who should be notified?
• In a multicenter trial, which term refers to a committee organized by a sponsor to coordinate the conduct of the trial?
• What describes the stopping rules or discontinuation criteria for the trial?
• If deviations from the original statistical plan occur, what is required for documentation?
• What does the Introduction convey about the product's identity and research rationale?
• Which document records the normal values and ranges for tests used in the protocol?
• Phase II typically starts with initiation of studies in which population?
• Which of the following is an objective of the ICH safety guidance?
• Which information must be specified about treatments for each trial group?
• What is the primary purpose of allocating trial-related duties and functions before trial start?
• To document informed consent, which documents are described as used?
• Essential Documents for the Conduct of a Clinical Trial are intended to permit evaluation of which aspects?
• Which document provides instructions for handling of investigational products and trial-related materials?
• Who keeps the Subject Identification Code List, a confidential list of names of all subjects allocated to trial numbers and the ability to reveal identity when needed?
• Which category requires reporting within 15 calendar days after first knowledge?
• Essential documents retention extension: It may be longer if required by what?
• Before initiating a clinical trial, how should foreseeable risks and inconveniences be weighed in relation to anticipated benefits for the subject and society?
• SUSARs require expedited reporting to regulatory authorities within what general timeframe?
• Who maintains the confidential Subject Identification Code List?
• What should the analysis plan address?
• Which of the following is required for an independent data-monitoring committee (IDMC) to effectively operate?
• Who should the sponsor designate to advise on trial-related medical questions or problems?
• Which statement about the investigational product and protocol is true?
• Which term is a written evaluation by the sponsor's auditor of the results of the audit?
• Which topic describes the procedural aspect of submitting expedited ADR reports?
• Global assessment variables are typically implemented as what kind of scale?
• Which term describes adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements?
• What is the purpose of maintaining a system for retrieving investigational products and documenting retrieval?
• Which item should be included to provide background by referencing literature and data?
• Which term is a written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations and, if appropriate, on financial matters?
• Which statements best describes what is subject to expedited reporting for adverse drug reactions?
• What entity is responsible for deciding whether a reaction in a trial using an active comparator or placebo should be reported to the manufacturer or to regulatory agencies?
• In Phase I, pharmacokinetic studies may be conducted in which subjects?
• A unique identifier assigned by the investigator to protect subject identity when reporting trial data is called what?
• Who may be designated to maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s)?
• In nonclinical pharmacokinetics, which aspect is specifically addressed?
• What recruitment capability must the investigator demonstrate for the trial?
• Which term describes a systematic and independent examination of trial related activities and documents to determine whether they were conducted and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's SOPs, GCP, and applicable regulatory requirements?
• Which term denotes the regulatory framework governing clinical trials of investigational products?
• What documentation should the sponsor obtain regarding IRB/IEC re-approvals or reevaluations?
• Which definition best describes a Serious Adverse Event (SAE) in GCP?
• Before entering an agreement with an investigator, what should the sponsor provide?
• Which topic focuses on presenting data and identifying the subjects to be evaluated?
• Blinding is intended to limit bias arising from knowledge of treatment in which aspects?
• Which document records that the investigator is informed in a timely manner of relevant information as it becomes available?
• Which document provides the written information given to trial subjects to support informed consent?
• What documentation should be provided to sponsor and IRB/IEC if termination occurs without sponsor agreement?
• Which design typically involves conducting trials at more than one site to gather diverse data?
• Which trial type has a rationale and design that rests on earlier work, and should have clear and precise objectives, though those objectives may not lead to simple tests?
• Which statement best describes the role of the investigator regarding monitoring and auditing?
• What is a primary purpose of packaging for the investigational product?
• Which element describes the route of administration, dosage, dosage regimen, and treatment periods?
• Phase III aims to complete the information needed to support what?